US-based digital health company Eden has introduced a new gummy product designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format.
Eden said that its new product is the world’s first compounded semaglutide gummy, and its format would change the way people approach GLP-1 programmes in the US.
The new GLP-1 gummy provides the same active ingredient as compounded semaglutide.
Also, it simplifies medication adherence for individuals, when prescribed by its network of healthcare providers, said the digital health company.
Eden president Josh Khan said: “At Eden, we are committed to making transformative healthcare accessible and convenient.
“With this first-of-its-kind gummy, we’ve removed barriers like needles and discomfort, empowering individuals to explore personalised care programs with their healthcare providers to achieve their health goals with a format that fits into their lives.”
Eden said its new gummy product will address the increasing demand for more user-friendly alternatives to traditional medications.
The company aims to address their patients’ demand for a more palatable, easier option compared to oral semaglutide droppers.
In addition, Eden is offering the patients a doctor-led weight loss programme, through a network of healthcare providers.
The members will get access to personalised medical consultations, custom care plans, on-demand workouts, and customised meal plans to support their metabolic health journey.
Eden is offering the new semaglutide gummy through subscription plans starting at $246 per month, after the patients are determined eligible for treatment by a licensed physician.
Eden CEO Adam McBride said: “Eden is at the forefront of metabolic health innovation. With this gummy format, we’re improving access and empowering individuals to take control of their health. It’s a game changer.”
